论文部分内容阅读
目的评价口服非诺贝特片与非诺贝特缓释胶囊治疗高脂血症的成本-效果。方法运用药物经济学成本分析的方法将高血脂门诊患者共100例,随机分为两组,分别给予非诺贝特片与非诺贝特缓释胶囊,30天为一疗程。根据药物经济学计算两种治疗方案的成本效果分析。结果非诺贝特片组与非诺贝特缓释胶囊组成本分别为220.7与329.6元,有效率分别为88%与94%,成本-效果比分别为250.8与350.6;缓释胶囊组相对于普通片剂组的增量成本-效果比为1815。结论普通片剂用药方案治疗高脂血症较佳。
Objective To evaluate the cost-effectiveness of oral fenofibrate and fenofibrate sustained release capsules in the treatment of hyperlipidemia. Methods A total of 100 hyperlipidemic patients were randomly divided into two groups according to the cost-benefit analysis of pharmacoeconomics. Fenofibrate and fenofibrate sustained-release capsules were given respectively. One course of treatment was 30 days. Cost effectiveness analysis of two treatment options based on pharmacoeconomics. Results The contents of fenofibrate and fenofibrate sustained-release capsules were 220.7 and 329.6 yuan respectively, the effective rates were 88% and 94%, respectively, and the cost-effectiveness ratios were 250.8 and 350.6 respectively. The incremental cost-effectiveness ratio for the normal tablet group was 1815. Conclusion Ordinary tablet regimen for the treatment of hyperlipidemia is better.